||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Allergy Therapeutics Share Discussion Threads
Showing 3326 to 3350 of 3350 messages
|Some positive news ahead of March 29th. Hopefully more to come before the month is out.|
|I actually expected 30p to be broken by the 29th but now that the sheer huge upside potential is being seen by an increased audience my expectations are up to see 35p and 40p broached on the proviso that the news on the USA is as positive as has been indicated and we get some left field news on all of the other irons in the fire.
All 100% impo/dyor
No ramp intended and or required|
|Looking more like a sustainable push towards 30p....|
|Could we be about to breakout.....|
|Gently does it...March already!|
|Able to sell at 25.45p
|If they go alone they will likely need more cash but given the longer-term potential that doesn't concern me.|
|Well Gold digger, if they do make their interims on March 29th, this should pop it's cork if my hunch is right. It has been a long time coming. The failure last year was costly from many perspectives. But they are a solid business with an ever widening portfolio.
My question is are they big enough to develop all of these products. When I read headlines saying xyz from AGY is 'TALKING UP' prospects of etc etc, it make me think, cash call must be in the wind.
Happy to sit tight now.|
|There's a new interview on Directors talk with Dr Gary Waanders, Director of Healthcare Research at Zeus Capital who talks about Acrovac and Allegy Therapeutics in general:
|Allergy Therapeutics CEO Murray Skinner speaks to Proactive about their phase I clinical study of Acarovac MPL receiving official sign-off in Spain.
A total of 32 patients will receive Acarovac, which will be administered at two different doses. The trial is expected to take 12 months from start to finish.
|Another small step towards the end-game. I still think we'll drift back in the short-term but am happy to be proved wrong. These are still very cheap given the potential so I plan to add as cash allows throughout 2017.|
|And more good news, March 29th could see this go through the next threshold (30p) if it hasn't done so before.
All of this takes time and more importantly......cash!|
I actually don't see this drifting too much. There is so much good stuff around however the price is being weighed down by last years failure in the USA.
March 29th could unclip that chain when we get some meat on the bones as to where we are in relation to the new trials.
There is little doubt that they are very upbeat with what they have been saying and allowing to be said of late.
Patience is needed in stocks like these.
and no more set backs!
|Looks like we'll drift for a while as is the way of things. I'm hoping its back at 18p come April so I can top-up with the new tax year's ISA allowance!|
|Is it starting to pull back or are we poised for the attack on 30p?|
|Upside still to be seen according to analyst.
Allergy Therapeutics (LON:AGY) will take its Polyvac vaccine for peanut allergy into a phase I clinical trial after it delivered positive pre-clinical results.
The findings showed a single dose of the company's unique adjuvant when combined with recombinant peanut allergen successfully protected against the serious allergic reaction anaphylaxis.
The company is developing Polyvac as a short course of injections that is safer and more effective than the current treatments.
“Hundreds of patients die each year in the United States as a result of food allergies (mainly peanut) and we are committed to saving these lives,” said Allergy Therapeutics chief executive Manuel Llobet.
“This peanut vaccine programme complements our current range of marketed ultra-short course vaccines in terms of safety, efficacy and improved patient convenience."
The shares rose 6% in afternoon trade to 27.5p. However the company’s broker, finnCap, thinks they have further to go.
Analyst Mark Brewer points out Allergy trades on an enterprise value/sales multiple of just two-times when its peers are on 3.2-times.
He reckons the shares are worth 43p each with “substantial further upside” as its hay fever drug Pollinex Quattro progresses through the development phases.
“We currently attribute no value to Polyvac Peanut and will re-assess as it moves into human studies,” said Brewer.
---adds broker comment, share price---|
|Medical director Dr Matthias Kramer talks to Proactiveinvestors.
|I wouldn't get too excited. New products such as this take ages to get to the market and of course lot's of cash.
Steady and solid progress is being seen.
For me, it is March 29th when I look forward to meat on the bones.
|Yep. Wait until this gets mentioned in the press|
|I have been waiting a long time for this to rocket, must be over 10 years since I bought. Have help throughout the pain of FDA issues. Hope this carries on up as my investment is now working. Good pipeline of products going forward|
|I know we have heard about AGY's innovative adjuvants before, but is this the first time we have heard the term "Virus like particles" (VLPs) when referring to one of their new adjuvants?
(jimmyloser: post #3200, very good!)|
|Hence all the publicity and news on Bencard a few weeks ago!! and the going public in the press.
All these things are stage managed and whoever is doing it, is doing a great job!!
Watch the press and world media to-day!
|Now we know the what stirred those pigeons. Good news. Suddenly a whole new opportunity looks like a reality|
|And to think you have been able to buy these shares for peanuts!!
Incredible piece of news to wake me from my slumbers this morning.
Well Done all at AGY!
I said yesterday that something had stirred this!|
|Something has stirred the pigeons here in the last few minutes....mm|